Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25670282 | 0.91 | CA2 (0.53) | CA2CA1MAPK1CTSKCTSS | |
| SCHEMBL26100054 | 0.91 | KMT2A (0.38) | CA2CA1GAAMEN1KMT2A | |
| SCHEMBL1922911 | 0.87 | CA2 (0.47) | CA2CA1MAPK1CTSKCTSS | |
| SCHEMBL24360474 | 0.87 | CA2 (0.50) | CA2CA1MAPK1CTSKCTSS | |
| SCHEMBL4458553 | 0.87 | CA2 (0.50) | CA2CA1MAPK1CTSKCTSS | |
| SCHEMBL20002265 | 0.87 | CA2 (0.50) | CA2CA1MAPK1CTSKCTSS | |
| SCHEMBL31235985 | 0.85 | CA2 (0.53) | CA2CA1MAPK1CTSK | |
| Water SCHEMBL28721777 | 0.85 | CA2 (0.48) | CA2CA1MAPK1CTSKCTSS | |
| SCHEMBL22035852 | 0.85 | CA2 (0.53) | CA2CA1MAPK1CTSK | |
| SCHEMBL21259199 | 0.85 | CA2 (0.53) | CA2CA1MAPK1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328619-B1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | Baxalta GmbH (CH) | 2016-12-07 | — | — | EP | disclosed |
| EP-2328619-B1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | Baxalta GmbH (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-8962549-B2 | Polymeric benzyl carbonate-derivatives | BAXTER INTERNATIONAL INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962549-B2 | Polymeric benzyl carbonate-derivatives | BAXTER INTERNATIONAL INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962549-B2 | Polymeric benzyl carbonate-derivatives | BAXTER INTERNATIONAL INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140128445-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER HEALTHCARE SA (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20140128445-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER HEALTHCARE SA (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20140128445-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER HEALTHCARE SA (CH) | 2014-05-08 | — | — | US | disclosed |
| US-8653131-B2 | Polymeric benzyl carbonate-derivatives | BAXTER HEALTHCARE S.A. (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653131-B2 | Polymeric benzyl carbonate-derivatives | BAXTER HEALTHCARE S.A. (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653131-B2 | Polymeric benzyl carbonate-derivatives | BAXTER HEALTHCARE S.A. (CH) | 2014-02-18 | — | — | US | disclosed |
| WO-2010022320-A2 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER INTERNATIONAL INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048483-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER HEALTHCARE S.A. (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048483-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER HEALTHCARE S.A. (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048483-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | BAXTER HEALTHCARE S.A. (CH) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048483-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | SI, SLC1A5, BCAT1 | CA2 71/4885CA1 38/4885MAPK1 4501/4885 |
| US-20140128445-A1 | POLYMERIC BENZYL CARBONATE-DERIVATIVES | SI, SLC1A5, BCAT1 | CA2 71/4885CA1 38/4885MAPK1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.